Innoviva, Inc. (NASDAQ:INVA) Shares Bought by US Bancorp DE

US Bancorp DE raised its position in Innoviva, Inc. (NASDAQ:INVA) by 356.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 12,753 shares of the biotechnology company’s stock after acquiring an additional 9,956 shares during the quarter. US Bancorp DE’s holdings in Innoviva were worth $231,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of INVA. BOKF NA boosted its stake in shares of Innoviva by 2.3% during the 4th quarter. BOKF NA now owns 28,648 shares of the biotechnology company’s stock valued at $495,000 after buying an additional 641 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Innoviva by 10.3% during the 1st quarter. Farther Finance Advisors LLC now owns 8,516 shares of the biotechnology company’s stock valued at $153,000 after buying an additional 795 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Innoviva by 3.8% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,490 shares of the biotechnology company’s stock valued at $546,000 after buying an additional 1,162 shares during the last quarter. Sterling Capital Management LLC boosted its stake in shares of Innoviva by 6.8% during the 4th quarter. Sterling Capital Management LLC now owns 22,924 shares of the biotechnology company’s stock valued at $398,000 after buying an additional 1,452 shares during the last quarter. Finally, Kendall Capital Management boosted its stake in shares of Innoviva by 4.5% during the 1st quarter. Kendall Capital Management now owns 35,115 shares of the biotechnology company’s stock valued at $637,000 after buying an additional 1,500 shares during the last quarter. Institutional investors and hedge funds own 99.12% of the company’s stock.

Innoviva Stock Performance

Shares of INVA opened at $20.88 on Friday. The business’s fifty day moving average price is $19.84 and its 200 day moving average price is $18.79. Innoviva, Inc. has a 12-month low of $16.67 and a 12-month high of $22.00. The stock has a market capitalization of $1.31 billion, a PE ratio of 67.36 and a beta of 0.38. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.64 and a quick ratio of 2.44.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings data on Wednesday, August 6th. The biotechnology company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.57 by $0.20. The firm had revenue of $100.28 million for the quarter, compared to analysts’ expectations of $87.10 million. Innoviva had a return on equity of 18.67% and a net margin of 10.44%. Equities research analysts forecast that Innoviva, Inc. will post 0.33 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on INVA. Cantor Fitzgerald began coverage on Innoviva in a research note on Friday, July 11th. They set an “overweight” rating and a $26.00 target price for the company. HC Wainwright increased their target price on Innoviva from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Monday. Wall Street Zen upgraded Innoviva from a “hold” rating to a “buy” rating in a research note on Wednesday, April 30th. Finally, Oppenheimer began coverage on Innoviva in a research note on Monday. They set an “outperform” rating and a $45.00 target price for the company. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $42.75.

Innoviva Company Profile

Innoviva, Inc engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company’s products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.